Orca Bio

Orca Bio is a late-stage biotechnology company developing high-precision allogeneic cell therapies for hematologic malignancies and autoimmune diseases. Its investigational products combine precisely selected populations of natural immune cells and stem cells — notably highly purified regulatory T cells (Tregs), hematopoietic stem cells and conventional T cells — with the aim of replacing a patient's diseased blood and immune system while achieving balanced immune reconstitution. The stated clinical goal is to reduce the trade-off patients face between cancer relapse and treatment-related risks such as graft-versus-host disease (GvHD) and infection following conventional allogeneic or autologous transplant.

The lead candidate, Orca-T, is an allogeneic T-cell immunotherapy for hematologic malignancies including acute myeloid leukemia (AML), acute lymphocytic/lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS), derived from related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the FDA for prevention of GvHD or death in patients eligible for hematopoietic stem cell transplant. Its Biologics License Application was accepted under Priority Review with a PDUFA target action date of April 6, 2026. Orca Bio's website states that TREGZI received U.S. FDA approval as a precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies. A second-generation candidate, Orca-Q, targets patients with AML, MDS or mixed phenotype acute leukemia (MPAL) and is described as designed to work without a fully matched donor; it is in an expanded Phase 1b study (NCT03802695). New programs evaluate Orca-T and Orca-Q in reduced intensity conditioning (RIC) and nonmyeloablative (NMA) settings, including the Phase 2 SERENE-T trial (NCT07216443) in AML and MDS.

Secondary profiles describe the enabling technology as "OrcaSort," a proprietary single-cell sorting and purification platform, and list the company as headquartered in Menlo Park, California with cGMP manufacturing in Sacramento, California. Founding year is reported inconsistently across sources (2016 in third-party profiles).

Founding story

Orca Bio was co-founded by Ivan Dimov, Nate Fernhoff and Jeroen Bekaert; third-party profiles state Dimov launched the company in 2016 and served as CEO. Fernhoff, a co-inventor of Orca-Q, was previously a postdoctoral scholar in Irving Weissman's laboratory at Stanford, and Dimov was a Siebel Fellow and visiting instructor in the same laboratory, linking the company's origins to Stanford stem cell research.

Business model

Orca Bio is a clinical- and pre-commercial-stage therapeutics developer: it funds internal R&D and manufacturing through venture equity and debt, advances proprietary cell therapy candidates through clinical trials and FDA review, and intends to commercialize approved products directly, having built its own commercial organization and centralized manufacturing capacity rather than out-licensing.

No product revenue is described in the sources; the company has been financed by equity rounds (through Series F) and a Silicon Valley Bank credit facility, with future revenue contingent on commercialization of Orca-T/TREGZI following FDA action.

Traction

The pivotal Phase 3 Precision-T study enrolled 187 patients across 19 U.S. centers, exceeding an original target of 174, and met its primary endpoint with a statistically significant improvement in survival free of moderate-to-severe chronic GvHD; results were published in Blood. The FDA accepted the Orca-T BLA under Priority Review in October 2025 with an April 6, 2026 PDUFA date, and the company's site announces FDA approval of TREGZI. Headcount is reported at approximately 288 as of January 2026.

Latest developments

On January 9, 2026 Orca Bio announced $250M in aggregate new equity from its two most recent rounds — a previously undisclosed Series E completed in 2024 and a Series F closed in December 2025 led by Lightspeed Venture Partners, with the spokesperson describing the amounts as comparable — plus a 2025 amendment to its Silicon Valley Bank credit facility providing up to $100M of additional liquidity. Proceeds fund commercial readiness ahead of the April 6, 2026 Orca-T PDUFA date, East Coast manufacturing capacity, and two new clinical programs: the Phase 2 SERENE-T study (NCT07216443) of Orca-T in AML/MDS under RIC or NMA conditioning, and an expanded Phase 1b of Orca-Q (NCT03802695) with three additional cohorts covering matched related/unrelated, 7/8 mismatched unrelated and haploidentical donors. The company website announces U.S. FDA approval of TREGZI.